Al M - Search Results

1

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.

Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J. Whiting P, et al. Among authors: al m. Health Technol Assess. 2014 Mar;18(18):1-106. doi: 10.3310/hta18180. Health Technol Assess. 2014. PMID: 24656117 Free PMC article. Review.

2

Costs, effects and C/E-ratios alongside a clinical trial.

van Hout BA, Al MJ, Gordon GS, Rutten FF. van Hout BA, et al. Among authors: al mj. Health Econ. 1994 Sep-Oct;3(5):309-19. doi: 10.1002/hec.4730030505. Health Econ. 1994. PMID: 7827647

3

Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis.

Al MJ, Koopmanschap MA, van Enckevort PJ, Geertsma A, van der Bij W, de Boer WJ, TenVergert EM. Al MJ, et al. Chest. 1998 Jan;113(1):124-30. doi: 10.1378/chest.113.1.124. Chest. 1998. PMID: 9440579

4

The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.

Al MJ, Michel BC, Rutten FF. Al MJ, et al. Pharmacoeconomics. 1996 Aug;10(2):141-51. doi: 10.2165/00019053-199610020-00006. Pharmacoeconomics. 1996. PMID: 10163417 Clinical Trial.

5

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.

Lamers LM, Stupp R, van den Bent MJ, Al MJ, Gorlia T, Wasserfallen JB, Mittmann N, Jin Seung S, Crott R, Uyl-de Groot CA; EORTC 26981/22981 NCI-C CE3 Intergroup Study. Lamers LM, et al. Among authors: al mj. Cancer. 2008 Mar 15;112(6):1337-44. doi: 10.1002/cncr.23297. Cancer. 2008. PMID: 18213621 Free article. Clinical Trial.

6

The cost utility of solifenacin in the treatment of overactive bladder.

Hakkaart L, Verboom P, Phillips R, Al MJ. Hakkaart L, et al. Int Urol Nephrol. 2009;41(2):293-8. doi: 10.1007/s11255-008-9448-2. Epub 2008 Aug 15. Int Urol Nephrol. 2009. PMID: 18704742

7

Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.

Oppe M, Al M, Rutten-van Mölken M. Oppe M, et al. Among authors: al m. Pharmacoeconomics. 2011 Mar;29(3):239-50. doi: 10.2165/11539870-000000000-00000. Pharmacoeconomics. 2011. PMID: 21142288

8

Association between lung function and exacerbation frequency in patients with COPD.

Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Mölken MR. Hoogendoorn M, et al. Among authors: al m. Int J Chron Obstruct Pulmon Dis. 2010 Dec 9;5:435-44. doi: 10.2147/COPD.S13826. Int J Chron Obstruct Pulmon Dis. 2010. PMID: 21191438 Free PMC article. Review.

9

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.

Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL. Hoogendoorn M, et al. Among authors: al mj. Value Health. 2011 Dec;14(8):1039-47. doi: 10.1016/j.jval.2011.06.008. Epub 2011 Sep 22. Value Health. 2011. PMID: 22152172 Free article.

10

Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.

Hoogendoorn M, Al MJ, Beeh KM, Bowles D, Graf von der Schulenburg JM, Lungershausen J, Monz BU, Schmidt H, Vogelmeier C, Rutten-van Mölken MP. Hoogendoorn M, et al. Among authors: al mj. Eur Respir J. 2013 Mar;41(3):556-64. doi: 10.1183/09031936.00027212. Epub 2012 Jun 14. Eur Respir J. 2013. PMID: 22700844 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

160 results

Search Page